33 results about "U87" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses a preparation method of a homologous tumor cell and American ginseng composite exosome, and belongs to the field of functional medical materials and nanotechnologies, and the preparation method comprises the following steps: S1, separating a U87 cell exosome from a U87 cell by using a continuous ultracentrifugation method, and preparing U87-Exos for later use; s2, separating American ginseng exosomes from American ginseng rhizomes by using a continuous ultracentrifugation method, and preparing AG-Exos for later use; s3, the U87-Exos obtained in the step S1 and the AG-Exos obtained in the step S2 are subjected to extrusion compounding, and U87 / AG-Exos is prepared; s4, temozolomide and resveratrol are dissolved in a solvent and mixed with the U87 / AG-Exos obtained in the step S3, and then the mixed solution is subjected to ultrasonic treatment. According to the exosome preparation method, a medicine delivery system based on homologous tumor cell composite Exos is prepared, TMZ and RES are jointly delivered and used for treating GBM, the medicine delivery system is based on the concept of traditional Chinese medicine combination therapy, the limitation of traditional chemotherapy is overcome, and a promising strategy is provided for treating GBM.

The invention discloses cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC is obtained by modifying a target protein ligand with a cell-penetrating peptide and an enzyme-sensitive Linker (GFLG) as an antitumor drug, has the capability of releasing the PDC type PROTAC under the catalysis of cathepsin B, has small influence on the cell activity of U251 cells, U87 cells and HEK293 cells, has proliferation inhibition activity on the U251 cells and the U87 cells, and can be used for preparing an antitumor drug. The polypeptide can degrade target proteins in U251 cells and U87 cells, can induce apoptosis of the U251 cells and the U87 cells, has an influence on the cycle of the U251 cells, can be used for preparing antitumor drugs (in the aspects of targeted protein degradation and membrane permeation), has a good application prospect in preparation of drugs targeting human brain glioma cells, and can be used in another important field of PROTAC drug development.

Through extensive and deep research, a new path Parkin / Park / Mul1 / Mfn2 for regulating and controlling the drug resistance of a tumor chemotherapy temozolomide (TMZ) drug by the TRPC5 is found, and the new path has a close relationship with the generation of the drug resistance of the tumor chemotherapy temozolomide (TMZ) drug. Compared with primary cells U87 and U251, the expression level of the TRPC5 in temozolomide tolerant cells U87R and U251R is remarkably improved, and a mitochondrial autophagy pathway is activated. By reducing the expression of the TRPC5 gene, the sensitivity of a cell strain to a temozolomide drug can be enhanced, and the proliferation capacity of tumor cells can be inhibited. According to the invention, not only is new data provided for a malignant glioma drug resistance mechanism, but also a new target spot is provided for the design of anti-tumor drug resistance drugs.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

The invention relates to the technical field of biomedicine, in particular to cyclic polypeptide targeting CD36 protein and a radioactive tracer derived from the cyclic polypeptide. The preparation method comprises the following steps: condensing cyclic polypeptide targeting CD36 protein and dipolyethylene glycol serving as a connexon, coupling a chelating agent NOTA to form a labeled precursor NOTA-ZL01 targeting the CD36 protein, labeling radionuclide with the labeled precursor NOTA-ZL01 targeting the CD36 protein to form a radioactive tracer [68Ga] Ga-ZL01, and carrying out a reaction on the radioactive tracer [68Ga] Ga-ZL01 and the labeled precursor NOTA-ZL01 and the labeled precursor NOTA-ZL01 targeting the CD36 protein. Through in-vitro radiochemical property research and in-vivo stability research, the radioactive tracer [68Ga] Ga-ZL01 is found to be high in stability and hydrophilic; through cell uptake research and receptor binding force research, it is found that the radioactive tracer [68Ga] Ga-ZL01 has high affinity to CD36 protein expressed by U87 cells; the tumor imaging effect of the radioactive tracer [68Ga] Ga-ZL01 is investigated through small animal PET / CT, and it is found that the radioactive tracer [68Ga] Ga-ZL01 can be used for in-vivo imaging of CD36 positive glioblastoma.

The application discloses the application of Huaxingdan in the preparation of a glioma drug in the technical field of biology and medicine, detects the influence of Huaxingdan on the proliferation activity of glioma cells U251, U87 and A172 by using an MTT method in vitro, finds that Huaxingdan has a significant inhibitory effect on the proliferation of glioma cells, and is time and concentration dependent. The influence of Huaxingdan on the apoptosis of glioma cells U87 is detected by using a flow cytometry, and it is found that Huaxingdan can induce the apoptosis of U87 cells, and is concentration dependent. The animal experiment shows that Huaxingdan can effectively inhibit the growth of glioma cells in vivo, and the HE staining shows that Huaxingdan has no toxicity in vivo, and can be used as a drug for preventing and treating glioma.

This invention relates to a biomimetic nanodelivery system ANG-2-CMLNPs. The preparation method of ANG-2-CMLNPs includes the following steps: Step 1: Prepare EZ NPs using a one-step self-assembly method, then co-incubate them with siRNA to obtain siRNA-EZ NPs; Step 2: Prepare liposomes using a thin-film hydration method, then modify them with ANG-2; Step 3: Add U87 MG cells to cold PBS, centrifuge to remove intact cells and debris, and the resulting precipitate is the glioma cell membrane fusion membrane; Step 4: Mix the Angiopep-2 modified liposomes obtained in Step 2 with the glioma cell membrane fusion membrane obtained in Step 3, and sonicate to obtain a composite; Step 5: Co-extrude the composite obtained in Step 4 with the siRNA-EZ NPs obtained in Step 1 to obtain the biomimetic nanodelivery system ANG-2-CMLNPs; In the above preparation process, when EZ... When the mass ratio of NPs to siRNA is 125:1 and the mass ratio of ANG-2 modified liposomes to CM is 1:5, the prepared ANG-2-CMLNPs delivery system achieves the optimal functional balance between the ability to cross the blood-brain barrier (BBB) ​​and tumor targeting efficacy.

The invention relates to application of aconitine and a malignant glioma resisting medicine, and relates to the technical field of biological medicine. According to the application, multiple aconitine is applied to intervene in human brain astroblastoma U87-MG cells, and through a CCK-8 cell viability experiment, a Transwell cell migration experiment and a cell apoptosis experiment, it is found that the multiple aconitine can effectively inhibit growth and migration of the human brain astroblastoma U87-MG cells and promote U87-MG cell apoptosis, and then malignant progression of glioma is inhibited; a new medicine is provided for treatment of glioma, and the application prospect is good.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. It is found that platelet membrane glycoprotein VI (GP6) plays an important role in CHIKV infection SH-SY5Y and U87 cells, expression of GP6 is reduced, and CHIKV infection can be obviously inhibited. The invention provides an application of GP6 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, joint swelling, muscle pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The application relates to the technical field of biological medicine, and discloses application of Nilotinib in preparation of a drug for inhibiting p53-AKT interaction. Relying on a double-fluorescence reporting system NanoBRET system, high-throughput screening is completed at a live cell level, and it is determined that a tyrosine kinase inhibitor Nilotinib can inhibit p53-AKT interaction. Function verification shows that Nilotinib can dose-dependently destroy a p53-AKT complex in HEK293T tool cells and U87MG, T98G and other glioma cells, release the inhibition of p53 function, and induce cell apoptosis. The above results illustrate a new path of precise intervention with the "p53-AKT interface" as a target, and provide experimental basis for redirecting Nilotinib to overcome p53-related drug resistance.

This invention discloses a method for verifying TBCB glioblastoma and cell proliferation, belonging to the fields of bioinformatics and tumor molecular biology. S1: Constructing a TBCB knockdown model and verifying its effectiveness; S2: Obtaining transcriptome data from the knockdown group and control group using RNA-seq; S3: Obtaining a set of DEGs through differential expression analysis; S4: Performing disease enrichment analysis based on DisGeNET to obtain significantly enriched disease entries and screening for GBM / glioma-related entries; S5: Verifying the expression differences and clinical relevance of TBCB and GBM based on public databases (one or more of GEO / TCGA / CGGA); S6: Conducting an EdU incorporation experiment in U87 cells to quantitatively verify the effect of TBCB knockdown on cell proliferation. The verification method of this invention is more directly disease-targeting: by using DisGeNET disease enrichment, the DEGs set is directly mapped to specific disease entries such as "glioma / glioma," avoiding a focus solely on pathway levels.

The application discloses a preparation method and application of a novel dimeric RGD cyclic peptide nuclear medicine targeting integrin alpha v beta 3, relates to the fields of radiochemistry and biological medicine, and discloses a preparation method and application of a nuclide marker targeting alpha v beta 3 integrin. The alpha v beta 3 nuclear medicine designed and synthesized in the application has good in-vivo stability, pharmacokinetic properties, and strong targeting and uptake to U87MG tumor cells with high expression of alpha v beta 3, and has diagnosis or treatment properties, and is expected to become a nuclide nuclear medicine with good application prospect for targeting alpha v beta 3 induced tumors.

The invention provides a method for circularly screening tumor drug-resistant cell lines in vivo by using a mouse model and application thereof, and the method comprises the following steps: injecting human glioma cells U87MG into the brain of a BALB / c nude mouse in situ, and applying temozolomide (TMZ) drug pressure to screen tumor cell lines with different drug-resistant levels. The TMZ drug-resistant tumor cells are obtained step by step through multiple times of circulating in-vivo screening, and the cells continuously keep drug resistance in vitro. Then, through function verification, drug sensitivity analysis and transcriptome sequencing, the reliability of the screened drug-resistant cells on gene and function levels is confirmed, and differential expression non-coding RNA related to drug resistance, including newly found non-coding RNA, is found. According to the invention, the research on tumor drug resistance can be accelerated, a drug resistance related molecular mechanism is disclosed, and a new thought and a new tool are provided for new drug research and development and personalized treatment.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention belongs to the technical field of polypeptide drugs, and particularly relates to a series of polypeptides with an anti-cancer effect and application thereof. According to the invention, Rink amide MBHA amino resin is used as a solid phase carrier, modification is carried out according to an amino acid sequence of a template polypeptide Hymenochirin-1Pa (H-0): Ac-LKLSPKTKDTLKKVLKGAIKGAIAIASAMA-NH2, and on the basis of retaining key amino acid residues, original amino acids are replaced by R8 and S5 at the positions of i and i + 7 amino acids, so that the target stapling peptide is obtained. Compared with a template polypeptide H-0, the obtained stapled peptide has the advantage that the anti-tumor activity on human liver cancer cells Huh7, human non-small cell lung cancer cells A549, glioma cells U87 and colon cancer cells T84 can be obviously improved.

The application discloses a cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC is obtained by modifying a cell-penetrating peptide and an enzyme-sensitive linker (GFLG) to a PROTAC of an anti-tumor drug target protein ligand, has the ability to release the PDC type PROTAC under catalysis of cathepsin B, has a smaller influence on cell viability of U251 cells, U87 cells and HEK293 cells, has proliferation inhibition activity on the U251 cells and the U87 cells, can degrade target proteins in the U251 cells and the U87 cells, can induce apoptosis of the U251 cells and the U87 cells, has an influence on U251 cell cycles, can be used for preparing an anti-tumor drug (target protein degradation and membrane penetration), has a good application prospect in preparation of a drug for targeting human brain glioma cells, and can be used as another important field for PROTAC drug development.

The present invention discloses the application of substances that inhibit the activity and / or expression level of CDYL in the preparation of products for preventing and treating glioma. Experiments have proven that at the cellular level, knockdown of CDYL can inhibit the proliferation ability, migration ability, and invasion ability of U87MG cells; at the animal level, knockdown of CDYL in U87MG cells significantly inhibits the growth of U87MG subcutaneous transplantation or orthotopic glioma; further, intratumoral injection of AAV-shCDYL to interfere with the expression of CDYL in U87MG xenografts significantly inhibits the growth of xenografts. The present invention provides a potential new target for the clinical treatment of glioma, and also provides new ideas for combination treatment regimens and immunotherapy methods in the clinical treatment of glioma. The present invention has potential clinical value.

The present invention relates to the field of biomedical technologies, and particularly to a cyclic polypeptide targeting CD36 protein and a derived radioactive tracer. In the present invention, the cyclic polypeptide targeting CD36 protein is condensed with diglycol as a linker, and then chelator NOTA is coupled to form a labeling precursor NOTA-ZL01 targeting CD36 protein. After the labeling precursor NOTA-ZL01 targeting CD36 protein is labeled with a radionuclide, a radioactive tracer [68Ga]Ga-ZL01 is formed. Through in vitro radiochemical property studies and in vivo stability studies, it is found that the radioactive tracer [68Ga]Ga-ZL01 has strong stability and is hydrophilic; through cell uptake studies and receptor binding force studies, it is found that the radioactive tracer [68Ga]Ga-ZL01 has a high affinity for the CD36 protein expressed by U87 cells; through small animal PET / CT to investigate the tumor imaging effect of the radioactive tracer [68Ga]Ga-ZL01, it is found that it can be used for in vivo imaging of CD36-positive glioblastoma.

The invention belongs to the technical field of medicines, and discloses an ursolic acid derivative as shown in a formula I, a preparation method of the ursolic acid derivative and application of the ursolic acid derivative in resisting glioma. A new method is provided for structural modification of ursolic acid, and part of the compounds have an inhibiting effect on proliferation of glioma U87 cells and have the potential of serving as anti-glioma drugs. # imgabs0 #

The invention relates to the field of antibody detection, in particular to an antibody based on anti-glial acidic protein and application thereof. The invention provides a nano antibody Nb-14 for resisting human glial acidic protein, the amino acid sequence of the nano antibody Nb-14 is as shown in SEQ ID NO: 10, the EC50 of the nano antibody Nb-14 is equal to 2.45 * 10 <-6 > mol / L, and the endocytosis efficiency of the nano antibody Nb-14 in U87MG cells is gt; 90%; qualitative and quantitative detection of the neuroglial acidic protein can be realized, and high specificity and detection sensitivity are achieved.

The invention discloses beta-carboline-thiazole conjugates as well as a preparation method and anti-tumor application thereof, and belongs to the technical field of medicinal chemistry. Wherein the structure of the compound 8 is as shown in the specification, tryptophan protected by N-terminal t-butyloxycarboryl is taken as a starting raw material, and simple construction of the beta-carboline-thiazole conjugate is completed through a one-kettle thiazole formation reaction, acid-catalyzed Boc protecting group removal and Pictet-Spengler cascade reaction. The compound 8 has the beneficial effects that the structure is novel, the compound 8 has a good killing effect on a human gastric cancer cell strain MKN45, the IC50 value is 3.8 mu M, the compound 8 has a good inhibiting effect on a human glioblastoma cell strain U87, the raw materials of the preparation method are cheap and easy to obtain, the preparation process is simple and convenient, and the compound 8 is suitable for large-scale industrial production; .

The present invention discloses a technetium-99m labeled FAPI derivative containing dual pharmacophores with a structural general formula of 99m Tc]Tc-(HYNIC-PEG4-2F46)(Tricine / TPPTS), and a preparation method and application thereof. Through two steps of the synthesis of the ligand HYNIC-PEG4-2F46 and 99m the preparation of Tc]Tc-(HYNIC-PEG4-2F46)(Tricine / TPPTS), the 99m Tc]Tc-(HYNIC-PEG4-2F46)(Tricine / TPPTS) complex is obtained. The complex is easy to prepare, has high radiochemical purity and good stability, has high uptake and a high target-to-non-target ratio at the tumor site of U87MG tumor-bearing mice, and has specific binding to FAP in tumors, and is a novel tumor radioactive drug with clinical application value.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. The invention discovers that the nerve cilia protein 2 (NRP2) plays an important role in CHIKV infection SH-SY5Y and U87 cells, and the CHIKV infection can be obviously inhibited by down-regulating the expression of the NRP2. The invention provides an application of NRP2 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The present application relates to the field of natural products, in particular to a sesquiterpene and uric acid dimer compound of guaiane type and an extraction and separation method and application thereof. A new sesquiterpene and uric acid dimer compound of guaiane type is extracted and separated from Guizhoutianmingjing, and it is found that the compound has strong antitumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharyngeal carcinoma, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an alternative for broad-spectrum anticancer drugs. Moreover, in the paclitaxel-resistant human prostate cancer cell PC3, human cervical cancer cell Hela, human hepatoma cell HepG2 and human glioma cell U87, the compound also exhibits strong anticancer activity, indicating that it has the potential to treat paclitaxel-resistant patients.

This invention relates to the field of genetic engineering technology, disclosing a method for constructing a plasmid for knocking out the FOSB gene, the plasmid constructed by the above method, and the application of the plasmid in preparing transfection reagents for knocking out the FOSB gene in cell lines; it also discloses a FOSB gene knockout method based on the CRISPR-Cas9 system, FOSB gene knockout cells, and their applications. This invention provides a method for designing dual sgRNAs targeting exons 2 and 3 of the FOSB gene, overcoming technical bottlenecks such as polyploidy / alloidy in U87-MG cells, high DNA repair capacity, and easy phenotype recovery, significantly improving knockout efficiency, causing frameshift mutations, resulting in complete loss of FOSB protein function, and constructing a knockout vector based on the PX459 plasmid, adapted to U87-MG cells, solving the problem of low conventional transfection efficiency; and successfully constructing the FOSB gene knockout vector. ∆ / ∆ The U87 cell line can be stably passaged for a long time, has a stable genetic background, and does not lose the knockout phenotype, providing a standardized and reproducible experimental platform for FOSB gene function research and glioma mechanism exploration.

The invention discloses a naphthyridinone compound as well as a pharmaceutical composition and application thereof. The compound provided by the invention can effectively degrade BRD8 protein in LNCAP cells and U87 cells, and has certain anti-proliferative activity on the LNCAP cells. Therefore, the compound can be used for preparing medicines for preventing and / or treating diseases related to the BRD8 protein, such as medicines for preventing and / or treating diseases such as glioblastoma and prostatic cancer.

A method for bioengineering exosomes for cancer treatment. The method comprises the steps of isolating target tumor cells from a tissue sample, culturing the isolated target tumor cells, treating the cultured target tumor cells with cold atmospheric plasma to release exosomes from the target tumor cells, and collecting the released exosomes. The step of culturing the target tumor cells may comprise seeding the isolated target tumor cells in wells and incubating the target tumor cells in a culture media, for example, for 24 hours. The culture media may comprise Dulbecco's Modified Eagle Medium, an antibiotic and 10% fetal bovine serum. The step of culturing the target tumor cells may further comprise replacing the culture media with Dulbecco's Modified Eagle Medium and an antibiotic. The target tumor cells may comprise, for example, one of U87 cells, KKU-055 cells and triple negative MDA-MB-231 cells.

The invention relates to application of hyodeoxycholic acid and a malignant glioma resisting medicine, and relates to the technical field of biological medicine. The invention relates to an application of hyodeoxycholic acid, which is used for preparing a medicine for resisting malignant glioma. Human brain astroblastoma U87-MG cells are intervened by applying hyodeoxycholic acid, and through a CCK-8 cell viability experiment, a Transwell cell migration experiment and a cell apoptosis experiment, it is found that hyodeoxycholic acid can effectively inhibit growth and migration of the human brain astroblastoma U87-MG cells and promote U87-MG cell apoptosis, so that malignant progression of neuroglioma is inhibited, and the effect of treating neuroglioma is achieved. A new medicine is provided for treatment of glioma, and the application prospect is good.